729
Participants
Start Date
October 31, 2010
Primary Completion Date
December 31, 2021
Study Completion Date
December 31, 2026
Lenalidomide
oral administration
Bortezomib
intravenous or, following protocol amendment, subcutaneous administration
Dexamethasone
"oral administration~Dose of 20 mg/day for first 3 cycles. Dose of 10 mg/day for remaining cycles."
Autologous Stem Cell Transplant
Autologous refers to stem cells that are harvested from the participant to be a source of new blood cells after high-dose chemotherapy with melphalan.
Memorial Sloan Kettering Cancer Center, New York
Mount Sinai Medical Center, New York
Columbia University, New York
North Shore Long Island Jewish Health System, Lake Success
Roswell Park Cancer Institute, Buffalo
University of Rochester Medical Center, Rochester
University of Pittsburgh Medical Center, Pittsburgh
University of Pennsylvania Medical Center, Philadelphia
Fox Chase Cancer Center, Philadelphia
Wake Forest University, Winston-Salem
UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Duke University, Durham
Emory University, Atlanta
University of Florida, Gainesville
H. Lee Moffitt Cancer Center, Tampa
University of Alabama at Birmingham, Birmingham
Vanderbilt University, Nashville
University of Mississippi Medical Center, Jackson
Ohio State University Medical Center, Columbus
University of Michigan, Ann Arbor
Barbara Ann Karmanos Cancer Institute, Detroit
University of Chicago, Chicago
Ochsner Foundation Clinic, New Orleans
University of Texas Southwestern Medical Center, Dallas
Baylor College of Medicine, Houston
MD Anderson Cancer Center, Houston
Colorado Blood Cancer Institute, Denver
Mountain States Tumor Institute at St. Luke's Regional Medical Center, Boise
Arizona Comprehensive Cancer Center, Tucson
City of Hope, Duarte
University of California, San Francisco, San Francisco
Stanford University, Stanford
Fred Hutchinson Cancer Research Center, Seattle
University of California at San Diego, La Jolla
Newton-Wellesley Hospital, Newton
New Hampshire Oncology and Hematology, Concord
New Hampshire Oncology and Hematology, Hooksett
New Hampshire Oncology and Hematology, Laconia
State University of New York Downstate Medical Center, Brooklyn
Oregon Health and Sciences, Portland
Huntsman Cancer Institute, Salt Lake City
Eastern Maine Medical Center, Brewer
Massachusetts General Hospital, Boston
Dana-Farber Cancer Institute, Boston
Beth Israel Deaconess Medical Center, Boston
Cape Cod Healthcare, Hyannis
Celgene Corporation
INDUSTRY
Millennium Pharmaceuticals, Inc.
INDUSTRY
Massachusetts General Hospital
OTHER
Cape Cod Hospital
OTHER
Beth Israel Deaconess Medical Center
OTHER
Emory University
OTHER
University of Michigan
OTHER
Fox Chase Cancer Center
OTHER
Memorial Sloan Kettering Cancer Center
OTHER
Fred Hutchinson Cancer Center
OTHER
Barbara Ann Karmanos Cancer Institute
OTHER
Duke University
OTHER
University of California, San Francisco
OTHER
University of Chicago
OTHER
M.D. Anderson Cancer Center
OTHER
UNC Lineberger Comprehensive Cancer Center
OTHER
Roswell Park Cancer Institute
OTHER
Stanford University
OTHER
University of Mississippi Medical Center
OTHER
Icahn School of Medicine at Mount Sinai
OTHER
Wake Forest University Health Sciences
OTHER
University of Arizona
OTHER
OHSU Knight Cancer Institute
OTHER
Eastern Maine Medical Center
OTHER
University of California, San Diego
OTHER
University of Alabama at Birmingham
OTHER
University of Pittsburgh Medical Center
OTHER
Ochsner Health System
OTHER
University of Texas Southwestern Medical Center
OTHER
State University of New York - Downstate Medical Center
OTHER
Newton-Wellesley Hospital
OTHER
Baylor College of Medicine
OTHER
City of Hope Medical Center
OTHER
University of Florida
OTHER
Northwell Health
OTHER
H. Lee Moffitt Cancer Center and Research Institute
OTHER
Vanderbilt University Medical Center
OTHER
Ohio State University
OTHER
Huntsman Cancer Institute
OTHER
Columbia University
OTHER
Paul Richardson, MD
OTHER